Results 251 to 260 of about 56,186 (320)

Response to the letter Re: Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting. [PDF]

ESMO Open
Rugo HS, Layman RM, Lynce F, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Curigliano G, Brufsky A.   +9 more
europepmc   +1 more source

Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor. [PDF]

Int J Mol Sci
Demirkiran C, Bellone S, Ettorre VM, Mansolf M, Hartwich TMP, McNamara B, Greenman M, Yang-Hartwich Y, Ratner E, Santin NG, Sethi N, Palmieri L, Coma S, Pachter JA, Ottum S, Santin AD.   +15 more
europepmc   +1 more source

Current and future advances in practice: aromatase inhibitor-induced arthralgia. [PDF]

Rheumatol Adv Pract
Kim S, Chen N, Reid P.
europepmc   +1 more source

Correction to: "Adult Height Following Prepubertal Treatment With Antiandrogen, Aromatase Inhibitor, and Reduced Hydrocortisone in CAH".

J Clin Endocrinol Metab
europepmc   +1 more source

Acupuncture for Aromatase Inhibitor-Induced Arthralgia in Breast Cancer: An Umbrella Review. [PDF]

Breast Care (Basel)
Zhang Y, Han L, Yang R, Zhang C, Duan S, Li P, Hou J.   +6 more
europepmc   +1 more source

Lessons learned from a candidate gene study investigating aromatase inhibitor treatment outcome in breast cancer. [PDF]

NPJ Breast Cancer
Hoppe R, Winter S, Lo WY, Michailidou K, Bolla MK, Keeman R, Wang Q, Dennis J, Lush M, Kalari KR, Goetz MP, Wang L, Cairns J, Weinshilboum R, Shepherd L, Chen BE, Häberle L, Ruebner M, Beckmann MW, He W, Larson NL, Armasu SM, Schroth W, Chowbay B, Khor CC, Abubakar M, Antoniou AC, Brüning T, Castelao JE, Chang-Claude J, Nbcs Collaborators, Dörk T, Eccles DM, Figueroa JD, Gago-Dominguez M, García-Sáenz JA, Gündert M, Hack CC, Hamann U, Han S, Hooning MJ, Huebner H, Abctb Investigators, John EM, Ko YD, Kristensen VN, Linn S, Margolin S, Mavroudis D, Nevanlinna H, Neven P, Obi N, Park-Simon TW, Pylkäs K, Rashid MU, Romero A, Saloustros E, Sawyer EJ, Tapper WJ, Tomlinson I, Wendt C, Winqvist R, Dunning AM, Simard J, Hall P, Pharoah PDP, Schwab M, Couch FJ, Czene K, Fasching PA, Easton DF, Schmidt MK, Ingle JN, Brauch H.   +73 more
europepmc   +1 more source

Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial. [PDF]

Clin Cancer Res
Fasching PA, Slamon D, Nowecki Z, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, Huang CS, Chan A, Chia S, Martín M, Rugo HS, Loi S, Hurvitz S, Untch M, Afenjar K, Fresco R, Danyliv A, Ferrusi I, Li Z, Hortobagyi G.   +19 more
europepmc   +1 more source

PCAIs stimulate MAPK, PI3K/AKT pathways and ROS-Mediated apoptosis in aromatase inhibitor-resistant breast cancer cells while disrupting actin filaments and focal adhesion. [PDF]

Oncotarget
Lazarte JMS, Ofosu-Asante K, Tilghman SL, Lamango NS.   +3 more
europepmc   +1 more source

Adverse Drug Event-based Stratification of Tumor Mutations: A Case Study of Breast Cancer Patients Receiving Aromatase Inhibitors.

, 2014
Chen Wang, Michael T. Zimmermann, Naresh Prodduturi, Christopher G. Chute, Guoqian Jiang   +4 more
openalex   +1 more source

Genomic alterations are associated with response to aromatase inhibitor therapy for ER-positive postmenopausal ductal carcinoma in situ: (CALGB 40903, Alliance). [PDF]

Breast Cancer Res
Marks JR, Zhang D, Hardman T, Chen YY, Hall A, Simpson L, Hieken T, Bedrosian I, Price E, Sheng J, Dai Y, Lee M, Sibley AB, Owzar K, Hwang ES.   +14 more
europepmc   +1 more source